Safety and Efficacy of Kelulut Honey Eyedrops in Dry Eye Disease

Inclusion Criteria: 1. Age 18-50 years at the time of consent. 2. Clinical diagnosis of dry eye disease in at least one eye, based on symptoms and clinical signs (Symptomatic dry eye, defined as an OSDI score ≥ 13; objective evidence of tear film instability, such as TBUT \< 10 seconds in at least one eye) 3. Participants may be Treatment-naïve, OR on stable dry eye treatment for at least 2 weeks before enrollment. 4. Willing to use Kelulut honey eyedrops three times daily for 1 month as instructed. 5. Able and willing to attend all study visits (Baseline, Week 2, Week 4). Exclusion Criteria: 1. Known allergy or hypersensitivity to honey, bee products, or any component of the study formulations. 2. Active ocular infection or inflammation (e.g., infectious conjunctivitis, keratitis, uveitis). 3. Severe allergic conjunctivitis or other ocular surface diseases 4. Significant meibomian gland dysfunction or blepharitis 5. Ocular surgery or laser procedures within the past 6 months. 6. Use of topical ocular medications other than lubricants within the past 30 days 7. Contact lens wear within 1 week prior to baseline or expected during the study. 8. Punctal plugs or other lacrimal procedures within the last 3 months. 9. Systemic diseases that significantly affect the ocular surface and are unstable or uncontrolled (e.g., uncontrolled Sjögren's, uncontrolled rheumatoid arthritis, uncontrolled diabetes). 10. Participation in another clinical trial or receipt of an investigational product within the past 30 days. 11. Pregnant or breastfeeding women, or those planning pregnancy during the study.